McKesson Corporation

MCK

US58155Q1031

McKesson Corporation specializes in pharmaceutical product distribution. The group also offers technological services to healthcare companies. Net sales break down by activity as follows: - distribution of pharmaceutical products (87%); - distribution of medical and surgical products (4%); - other (1.6%): primarily technology services and software sales. The remaining net sales (7.4%) are from international activities.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Annual General Meeting

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for McKesson Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

578.3 USD

Average target price

611.7 USD

Spread / Average Target

+5.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
MCKESSON CORPORATION	+24.90%	74.8B
CARDINAL HEALTH, INC.	-7.00%	22.92B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+14.82%	8.74B
SINOPHARM GROUP CO. LTD.	-5.82%	7.94B
HUADONG MEDICINE CO., LTD	-33.26%	6.69B
H. LUNDBECK A/S	+20.70%	5.66B
EBOS GROUP LIMITED	-3.10%	4.02B
MEDIPAL HOLDINGS CORPORATION	+12.82%	3.41B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+7.79%	3.18B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	-14.25%	3.18B

Pharmaceuticals Wholesale

Market Closed - Nyse Other stock markets 04:00:02 2024-07-15 pm EDT			5-day change	1st Jan Change
578.3 ^USD	+0.28%		-1.91%	+24.90%

Jul. 15	Morgan Stanley Adjusts Price Target on McKesson to $612 From $581, Maintains Overweight Rating	MT
Jul. 09	AMN Healthcare Appoints Jim Hinton to Board of Directors Effective July 22	CI

Morgan Stanley Adjusts Price Target on McKesson to $612 From $581, Maintains Overweight Rating	Jul. 15	MT
AMN Healthcare Appoints Jim Hinton to Board of Directors Effective July 22	Jul. 09	CI
Baird Adjusts McKesson's Price Target to $694 From $679, Keeps Outperform Rating	Jul. 09	MT
Evercore ISI Adjusts Price Target on McKesson to $660 From $600, Maintains Outperform Rating	Jul. 09	MT
Mckesson Insider Sold Shares Worth $2,180,193, According to a Recent SEC Filing	Jul. 08	MT
Leerink Adjusts Price Target on McKesson to $700 From $617, Maintains Outperform Rating	Jul. 08	MT
Rhia Ventures Files an Exempt Solicitation Statement and Request Vote for the Proposal	Jun. 28	CI
Sector Update: Consumer Stocks Mixed in Late Afternoon Trading	Jun. 27	MT
Rite Aid seeks bankruptcy court approval to cut $2 billion debt	Jun. 27	RE
Independent Pharmacy Cooperative Announces New Supply Agreement with McKesson	Jun. 24	CI
Argus Adjusts Price Target on McKesson to $670 From $570	Jun. 24	MT
McKesson Corporation Receives a Shareholder Proposal from Rhia Ventures	Jun. 21	CI
McKesson Corporation Receives a Shareholder Proposal from John Chevedden	Jun. 21	CI
Deutsche Bank Adjusts Price Target on McKesson to $631 From $545	Jun. 14	MT
Mckesson Insider Sold Shares Worth $351,318, According to a Recent SEC Filing	Jun. 12	MT
Top law firms in US opioid lawsuits to get hundreds of millions in fees	Jun. 07	RE
Mckesson Insider Sold Shares Worth $2,155,761, According to a Recent SEC Filing	Jun. 06	MT
Mckesson Insider Sold Shares Worth $2,935,100, According to a Recent SEC Filing	Jun. 03	MT
Mckesson Corporation Elects Deborah Dunsire as New Director	Jun. 03	CI
McKesson Insider Sold Shares Worth $1,833,166, According to a Recent SEC Filing	May. 30	MT
Baird Adjusts Price Target on McKesson to $679 From $671	May. 29	MT
Mckesson Insider Sold Shares Worth $392,895, According to a Recent SEC Filing	May. 28	MT
Mckesson Insider Sold Shares Worth $7,116,764, According to a Recent SEC Filing	May. 28	MT
JPMorgan Adjusts McKesson Price Target to $656 From $589	May. 17	MT
McKesson Seeks Acquisitions	May. 16	CI

McKesson Corporation

Equities

MCK